Bayer has received approval from the Japanese Ministry of Health, Labor and Welfare to sell the drug finerenone under the brand name Kerendia. The drug is intended to treat chronic kidney disease and type 2 diabetes. Finerenone was previously approved for sale in the EU and the US.